JP3762222B2 - 改変型ＴＧＦ−βスーパーファミリータンパク質 - Google Patents

改変型ＴＧＦ−βスーパーファミリータンパク質 Download PDF

Info

Publication number
JP3762222B2
JP3762222B2 JP2000574560A JP2000574560A JP3762222B2 JP 3762222 B2 JP3762222 B2 JP 3762222B2 JP 2000574560 A JP2000574560 A JP 2000574560A JP 2000574560 A JP2000574560 A JP 2000574560A JP 3762222 B2 JP3762222 B2 JP 3762222B2
Authority
JP
Japan
Prior art keywords
protein
tgf
bmp
proteins
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000574560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003535019A (ja
Inventor
ヘルマン． オッパーマン，
メイ−シェイ． タイ，
ジョン マッカートニー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stryker Corp
Original Assignee
Stryker Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stryker Corp filed Critical Stryker Corp
Publication of JP2003535019A publication Critical patent/JP2003535019A/ja
Application granted granted Critical
Publication of JP3762222B2 publication Critical patent/JP3762222B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000574560A 1998-10-07 1999-10-07 改変型ＴＧＦ−βスーパーファミリータンパク質 Expired - Fee Related JP3762222B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10341898P 1998-10-07 1998-10-07
US60/103,418 1998-10-07
US37533399A 1999-08-16 1999-08-16
US09/375,333 1999-08-16
PCT/US1999/023372 WO2000020449A2 (en) 1998-10-07 1999-10-07 MODIFIED TGF-β SUPERFAMILY PROTEINS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005156477A Division JP2005320339A (ja) 1998-10-07 2005-05-27 改変型ＴＧＦ−βスーパーファミリータンパク質

Publications (2)

Publication Number Publication Date
JP2003535019A JP2003535019A (ja) 2003-11-25
JP3762222B2 true JP3762222B2 (ja) 2006-04-05

Family

ID=26800442

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2000574560A Expired - Fee Related JP3762222B2 (ja) 1998-10-07 1999-10-07 改変型ＴＧＦ−βスーパーファミリータンパク質
JP2005156477A Withdrawn JP2005320339A (ja) 1998-10-07 2005-05-27 改変型ＴＧＦ−βスーパーファミリータンパク質
JP2008162608A Withdrawn JP2008231125A (ja) 1998-10-07 2008-06-20 改変型ＴＧＦ−βスーパーファミリータンパク質
JP2010098044A Withdrawn JP2010180241A (ja) 1998-10-07 2010-04-21 改変型ＴＧＦ−βスーパーファミリータンパク質
JP2012200388A Pending JP2013014606A (ja) 1998-10-07 2012-09-12 改変型ＴＧＦ−βスーパーファミリータンパク質
JP2016000135A Pending JP2016056185A (ja) 1998-10-07 2016-01-04 改変型ＴＧＦ−βスーパーファミリータンパク質

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2005156477A Withdrawn JP2005320339A (ja) 1998-10-07 2005-05-27 改変型ＴＧＦ−βスーパーファミリータンパク質
JP2008162608A Withdrawn JP2008231125A (ja) 1998-10-07 2008-06-20 改変型ＴＧＦ−βスーパーファミリータンパク質
JP2010098044A Withdrawn JP2010180241A (ja) 1998-10-07 2010-04-21 改変型ＴＧＦ−βスーパーファミリータンパク質
JP2012200388A Pending JP2013014606A (ja) 1998-10-07 2012-09-12 改変型ＴＧＦ−βスーパーファミリータンパク質
JP2016000135A Pending JP2016056185A (ja) 1998-10-07 2016-01-04 改変型ＴＧＦ−βスーパーファミリータンパク質

Country Status (6)

Country Link
US (2) US20050250936A1 (enExample)
EP (2) EP1117805A2 (enExample)
JP (6) JP3762222B2 (enExample)
AU (1) AU1103900A (enExample)
CA (2) CA2345024C (enExample)
WO (1) WO2000020449A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007059A1 (en) * 1999-07-21 2001-02-01 University Of Southern California Matrix-targeted fusion polypeptides for tissue regeneration and wound healing
US6942853B2 (en) * 2001-01-09 2005-09-13 Queen Mary And Westfield College Latent fusion protein
US7141392B2 (en) 2001-01-09 2006-11-28 Queen Mary And Westfield College Latent fusion protein
JP2002306163A (ja) * 2001-04-11 2002-10-22 Chemo Sero Therapeut Res Inst 大腸菌を宿主とする遺伝子組換えヒトトロンビンの調製方法
FI116827B (fi) 2001-08-24 2006-03-15 Univ Zuerich Luun morfogeneettisen proteiinin deleetiomutantti, sitä sisältävä farmaseuttinen koostumus ja sen käyttö
ES2555956T3 (es) 2004-04-13 2016-01-11 St Vincent's Hospital Sydney Limited Método para modular el apetito
US20090042780A1 (en) * 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
US7795389B2 (en) 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
WO2006133457A2 (en) * 2005-06-09 2006-12-14 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Bone morphogenetic variants, compositions and methods of treatment
ATE514712T1 (de) 2005-12-26 2011-07-15 Yantai Zhenghai Bio Technology Co Ltd Aktivierte collagen-gerüstmaterialien und ihre speziellen kondensierten aktiven restorationsfaktoren
WO2008051526A2 (en) * 2006-10-23 2008-05-02 Stryker Corporation Bone morphogenetic proteins
ES2447516T3 (es) 2006-12-21 2014-03-12 Stryker Corporation Formulaciones de liberación sostenida que comprenden cristales BMP-7
AU2010211438B2 (en) * 2009-02-06 2016-04-14 Academisch Ziekenhuis Maastricht Truncated cystine-knot proteins
SG173634A1 (en) 2009-02-12 2011-09-29 Stryker Corp COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-ß SUPERFAMILY MEMBERS
WO2010093925A2 (en) 2009-02-12 2010-08-19 Stryker Corporation PERIPHERAL ADMINISTRATION OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS FOR TREATMENT OF SYSTEMIC DISORDERS AND DISEASE
US20120148539A1 (en) 2009-03-24 2012-06-14 Moulay Hicham Alaoui-Ismaili Methods and Compositions for Tissue Engineering
US20110224138A1 (en) 2009-09-09 2011-09-15 Julie Krop Methods for treating pain induced by injuries and diseases of an articular joint
CA2774024A1 (en) 2009-09-17 2011-03-24 Stryker Corporation Buffers for controlling the ph of bone morphogenetic proteins
JP2013514811A (ja) 2009-12-22 2013-05-02 ストライカー コーポレイション 免疫原性が抑制されたｂｍｐ−７変異体
EP2547328B1 (en) * 2010-02-11 2017-06-07 Ecole Polytechnique Fédérale de Lausanne (EPFL) Ccr7 ligand delivery and co-delivery in immunotherapy
US11078248B2 (en) 2010-03-19 2021-08-03 Lifenet Health BMP peptides and methods of use
CA2794167A1 (en) * 2010-03-24 2011-09-29 Lifenet Health Bmp-7 peptides & methods of use
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
PH12013500294A1 (en) * 2010-08-20 2017-08-23 Wyeth Llc Designer osteogenic proteins
US9856305B2 (en) 2010-08-20 2018-01-02 Wyeth Llc Designer osteogenic proteins
CN104271148A (zh) 2012-02-15 2015-01-07 洛桑聚合联合学院 红细胞结合性治疗剂
WO2014100689A1 (en) 2012-12-21 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
CA2911514A1 (en) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
LT3107563T (lt) 2014-02-21 2021-07-12 Ecole Polytechnique Fédérale De Lausanne (Epfl) Epfl-Tto Gliko-nukreipiantys terapiniai agenai
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CN109311956A (zh) 2015-08-25 2019-02-05 伊斯迪德股份公司 诱导组织形成的化合物及其应用
CN109311957A (zh) * 2015-08-25 2019-02-05 伊斯迪德股份公司 诱导组织形成的化合物及其应用
WO2017209519A1 (en) * 2016-05-31 2017-12-07 Mogam Institute For Biomedical Research Ab6 family designer ligands of tgf-beta superfamily
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности
EP3878856B1 (en) 2018-11-05 2025-06-18 Ajinomoto Co., Inc. Method for producing refolded protein by using flow microreactor, and protein refolding apparatus
CN115128147B (zh) * 2021-03-29 2025-02-11 盛禾(中国)生物制药有限公司 一种融合蛋白样品的快速分析方法
CN120603603A (zh) * 2023-01-12 2025-09-05 瑞泽恩制药公司 用于靶向递送TGFβ的组合物和方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002198A1 (en) * 1983-11-01 1985-05-23 Amgen Microbial expression of type i transforming growth factor, polypeptide analogs thereof and hybrid egf/tgf polypeptides
ZA874681B (en) 1986-07-01 1988-04-27 Genetics Inst Novel osteoinductive factors
US5106748A (en) 1986-07-01 1992-04-21 Genetics Institute, Inc. Dna sequences encoding 5 proteins
US4877864A (en) 1987-03-26 1989-10-31 Genetics Institute, Inc. Osteoinductive factors
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5108922A (en) 1986-07-01 1992-04-28 Genetics Institute, Inc. DNA sequences encoding BMP-1 products
US5155058A (en) 1986-11-07 1992-10-13 Canon Kabushiki Kaisha Method of making semiconductor memory device
US5221620A (en) * 1987-10-06 1993-06-22 Oncogen Cloning and expression of transforming growth factor β2
EP0372005A4 (en) * 1987-10-30 1990-06-26 Oncogen EXPRESSION SYSTEMS FOR THE PREPARATION OF POLYPEPTIDES IN PROKARYOTIC CELLS.
US5258494A (en) 1988-04-08 1993-11-02 Stryker Corporation Osteogenic proteins
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5250302A (en) 1988-04-08 1993-10-05 Stryker Corporation Osteogenic devices
US4968590A (en) 1988-04-08 1990-11-06 Stryker Corporation Osteogenic proteins and polypeptides
US5002965A (en) 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
CA2042577A1 (en) 1989-10-17 1991-04-18 Hermann Oppermann Osteogenic devices
AU6870791A (en) * 1989-10-18 1991-05-16 Creative Biomolecules, Inc. Biosynthetic constructs of tgf-beta
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
CA2084992A1 (en) * 1990-06-25 1991-12-26 Osi Pharmaceuticals, Inc. Tissue-derived tumor growth inhibitors, methods for preparation and uses thereof
DE69231946T2 (de) 1991-03-11 2002-04-04 Curis, Inc. Protein-induzierende morphogenese
KR100259827B1 (ko) * 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
US5807713A (en) * 1992-02-12 1998-09-15 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung DNA encoding growth/differentiation factor
EP1238986B1 (en) 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
EP1439190A1 (en) 1993-01-12 2004-07-21 The Johns Hopkins University School Of Medicine Growth differentiation factor-5
CA2124422A1 (en) * 1993-05-27 1994-11-28 Yukio Fujisawa Heterodimers of tgf-.beta. superfamily
EP0804214A4 (en) 1993-07-09 1998-05-20 Univ Johns Hopkins Med FACTOR 6 OF CELL GROWTH AND DIFFERENTIATION
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
DK0733109T3 (da) 1993-12-07 2006-07-03 Genetics Inst Llc BMP-12, BMP-13 og seneinducerende præparater dermed
TW459044B (en) * 1994-07-01 2001-10-11 Bioph Biotech Entw Pharm Gmbh Protein MP-121 of the TGF-β-like family
US6352972B1 (en) * 1995-06-06 2002-03-05 Marcel E. Nimni Bone morphogenetic proteins and their use in bone growth
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
US5674292A (en) 1995-06-07 1997-10-07 Stryker Corporation Terminally sterilized osteogenic devices and preparation thereof
US5932716A (en) 1995-07-26 1999-08-03 Creative Biomolecules, Inc. Morphogen-responsive regulatory elements
US6677432B1 (en) * 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
WO2009134891A2 (en) 2008-04-29 2009-11-05 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
US8750953B2 (en) 2008-02-19 2014-06-10 Covidien Lp Methods and systems for alerting practitioners to physiological conditions
EP2474639B1 (en) 2009-08-31 2019-04-17 Nippon Steel & Sumitomo Metal Corporation High-strength galvannealed steel sheet
WO2013033216A1 (en) 2011-08-29 2013-03-07 Massachusetts Institute Of Technology System and method for finding mood-dependent top selling/rated list
US9107654B2 (en) 2012-01-05 2015-08-18 Cook Medical Technologies Llc Attachment device for tissue approximation and retraction

Also Published As

Publication number Publication date
JP2010180241A (ja) 2010-08-19
CA2345024A1 (en) 2000-04-13
WO2000020449A2 (en) 2000-04-13
US20050250936A1 (en) 2005-11-10
WO2000020449A3 (en) 2000-10-12
EP2128260A2 (en) 2009-12-02
AU1103900A (en) 2000-04-26
JP2005320339A (ja) 2005-11-17
JP2003535019A (ja) 2003-11-25
US8518411B2 (en) 2013-08-27
JP2016056185A (ja) 2016-04-21
US20120122778A1 (en) 2012-05-17
JP2013014606A (ja) 2013-01-24
JP2008231125A (ja) 2008-10-02
CA2657302A1 (en) 2000-04-13
EP2128260A3 (en) 2010-06-16
CA2345024C (en) 2009-05-19
WO2000020449A9 (en) 2002-08-22
EP1117805A2 (en) 2001-07-25

Similar Documents

Publication Publication Date Title
JP3762222B2 (ja) 改変型ＴＧＦ−βスーパーファミリータンパク質
JP3971107B2 (ja) ＴＧＦ−βスーパーファミリー間のキメラタンパク質
EP2401293B1 (en) Designer ligands of tgf-beta superfamily
JP3982995B2 (ja) 形態形成タンパク質を含むＴＧＦ−βスーパーファミリー変異体メンバー
JP2008086319A (ja) ヘパリン結合能の亢進したポリペプチド変異体
AU717811B2 (en) Single chain analogs of the TGF-beta superfamily (morphons)
US20190135884A1 (en) Composition comprising an ab6 family designer ligand of tgf-beta superfamily for treating bone and cartilage disease and use thereof

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20051102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051115

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20051121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20051220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060112

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100120

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100120

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110120

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120120

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130120

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees